This report summarizes current recommendations regarding venous thromboembolism (VTE) prevention in elective and trauma spine surgery. Evidence indicates that the incidence of VTE without significant risk factors ranges from 0–10% in elective procedures when mechanical and/or chemoprophylaxis are used (Grade A). However, there is limited evidence to support a specific prophylaxis protocol, with the rate of VTE potentially higher in anterior versus posterior lumbar surgeries, lumbar versus cervical surgeries, and procedures involving more than four levels (Grade I). The optimal timing of VTE occurrence remains uncertain, with reports ranging from preoperative to up to 30 days postoperative, depending on screening protocols (Grade I).
The combined use of chemoprophylaxis and mechanical prophylaxis does not currently have sufficient evidence to establish superior effectiveness over either method alone (Grade I). In patients undergoing spine surgery for trauma without spinal cord injury, the VTE incidence is estimated between 1.4–6%, with higher rates observed in those with spinal cord injuries (Grade B). For oncologic spine procedures, VTE rates vary widely from 0–22% (Grade B). The continuation of anticoagulation appears safe, not increasing hemorrhagic complications in elective (Grade B) or trauma cases (Grade B).
While adding chemoprophylaxis to mechanical measures generally does not offer additional benefit for routine elective surgeries, it may be considered in high-risk patients or those undergoing anterior approaches (Grade C). Early postoperative rehabilitation could help reduce VTE risk (Grade C). In trauma patients, initiating chemoprophylaxis within 24–48 hours after ensuring no contraindications may be considered (Grade C). For malignant cases, evidence is insufficient to recommend specific timing or use of chemoprophylaxis.
Regarding pharmacologic agents, no definitive recommendation exists for particular drugs or bridge therapy timing due to limited evidence. Routine postoperative DVT screening does not significantly reduce PE risk; however, high-risk patient screening may be beneficial (Grade C). Overall, current evidence supports cautious, individualized VTE prophylaxis strategies, emphasizing high-risk patient identification and early mobilization.
Reference:
NASS 2nd Edition Guidelines for Antithrombotic Therapies for Adults Undergoing Spine Surgery – Guideline Summary – Guideline Central. (n.d.). https://www.guidelinecentral.com/guideline/4983470/#section-4983519
